Lukas C. Heukamp

17.2k total citations
175 papers, 6.1k citations indexed

About

Lukas C. Heukamp is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Lukas C. Heukamp has authored 175 papers receiving a total of 6.1k indexed citations (citations by other indexed papers that have themselves been cited), including 81 papers in Molecular Biology, 81 papers in Pulmonary and Respiratory Medicine and 62 papers in Oncology. Recurrent topics in Lukas C. Heukamp's work include Lung Cancer Treatments and Mutations (60 papers), Cancer Genomics and Diagnostics (25 papers) and Epigenetics and DNA Methylation (19 papers). Lukas C. Heukamp is often cited by papers focused on Lung Cancer Treatments and Mutations (60 papers), Cancer Genomics and Diagnostics (25 papers) and Epigenetics and DNA Methylation (19 papers). Lukas C. Heukamp collaborates with scholars based in Germany, United States and Netherlands. Lukas C. Heukamp's co-authors include Jörg Ellinger, Stefan C. Müller, Patrick J. Bastian, Reinhard Buettner, Alexander von Ruecker, Philip Kahl, Reinhard Büttner, Sebastian Rogenhofer, Johannes H. Schulte and Angelika Eggert and has published in prestigious journals such as Cell, Journal of Clinical Investigation and The Journal of Experimental Medicine.

In The Last Decade

Lukas C. Heukamp

171 papers receiving 6.0k citations

Peers

Lukas C. Heukamp

ONCOL

PRM

IMMUN

David S. Rickman United States

Oriol Casanovas Spain

Irina Ostrovnaya United States

Maria Cristina Manara Italy

Enrique de Álava Spain

Roland Penzel Germany

Christine Fuller United States

Eric A. Severson United States

Daniel Dumont Canada

Yoon‐La Choi South Korea

David S. Rickman United States

Lukas C. Heukamp

2.8k ×0.8

1.4k ×0.7

ONCOL

1.6k ×0.9

PRM

1.6k ×1.1

496 ×0.6

IMMUN

Citations per year, relative to Lukas C. Heukamp Lukas C. Heukamp (= 1×) peers David S. Rickman

Countries citing papers authored by Lukas C. Heukamp

Since Specialization

Citations

This map shows the geographic impact of Lukas C. Heukamp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lukas C. Heukamp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lukas C. Heukamp more than expected).

Fields of papers citing papers by Lukas C. Heukamp

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lukas C. Heukamp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lukas C. Heukamp. The network helps show where Lukas C. Heukamp may publish in the future.

Co-authorship network of co-authors of Lukas C. Heukamp

This figure shows the co-authorship network connecting the top 25 collaborators of Lukas C. Heukamp. A scholar is included among the top collaborators of Lukas C. Heukamp based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lukas C. Heukamp. Lukas C. Heukamp is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schmidt, Stefanie, David Horst, Markus Möbs, et al.. (2025). Detection of ESR1 Mutations in Tissue and Liquid Biopsy with Novel Next-Generation Sequencing and Digital Droplet PCR Assays: Insights from Multi-Center Real Life Data of Almost 6000 Patients. Cancers. 17(8). 1266–1266. 1 indexed citations

Pirngruber, Judith, Eva‐Maria Willing, Markus Falk, et al.. (2023). The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations. Current Oncology. 30(10). 8805–8814. 2 indexed citations

Wiesweg, Marcel, Martin Metzenmacher, Wilfried Eberhardt, et al.. (2021). BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy. European Journal of Cancer. 149. 211–221. 12 indexed citations

Bochtler, Tilmann, Volker Endris, Thomas Hielscher, et al.. (2020). Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary. International Journal of Cancer. 146(11). 3053–3064. 10 indexed citations

Mahjoubi, Linda, Franco Cecchi, Christophe Massard, et al.. (2018). Personalized therapy based on sequential molecular analysis leads to 30 months of survival in a patient with diffuse unresectable gastric linitis plastica. Tumori Journal. 104(6). NP38–NP41.

Prenzel, R., Kay Willborn, Cora Hallas, et al.. (2017). MA04.05 P53 Non-Disruptive Mutation is a Negative Predictive Factor for OS and PFS in EGFR M+ NSCLC Treated with TKI. Journal of Thoracic Oncology. 12(1). S359–S360. 2 indexed citations

Göktuna, Serkan İsmail, Kateryna Shostak, Tieu‐Lan Chau, et al.. (2016). The Prosurvival IKK-Related Kinase IKKϵ Integrates LPS and IL17A Signaling Cascades to Promote Wnt-Dependent Tumor Development in the Intestine. Cancer Research. 76(9). 2587–2599. 19 indexed citations

Delaunay, Sylvain, Francesca Rapino, Lars Tharun, et al.. (2016). Elp3 links tRNA modification to IRES-dependent translation of LEF1 to sustain metastasis in breast cancer. The Journal of Experimental Medicine. 213(11). 2503–2523. 131 indexed citations

Scheel, Andreas H., Manfred Dietel, Lukas C. Heukamp, et al.. (2016). Prädiktive PD-L1-Immunhistochemie beim nichtkleinzelligen Bronchialkarzinom. Aktueller Stand und Erfahrungen der ersten deutschen Harmonisierungsstudie. Der Pathologe. 37. 17 indexed citations

10.

Meder, Lydia, Katharina König, Luka Ozretić, et al.. (2015). NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas. International Journal of Cancer. 138(4). 927–938. 141 indexed citations

11.

Chatterjee, Sampurna, Caroline Wieczorek, Jakob Schöttle, et al.. (2014). Transient Antiangiogenic Treatment Improves Delivery of Cytotoxic Compounds and Therapeutic Outcome in Lung Cancer. Cancer Research. 74(10). 2816–2824. 28 indexed citations

12.

Dietlein, Felix, Lisa Thelen, Mladen Jokić, et al.. (2014). A Functional Cancer Genomics Screen Identifies a Druggable Synthetic Lethal Interaction between MSH3 and PRKDC. Cancer Discovery. 4(5). 592–605. 53 indexed citations

13.

Pallasch, Christian P., Ilya Leskov, Christian Braun, et al.. (2014). Sensitizing Protective Tumor Microenvironments to Antibody-Mediated Therapy. Cell. 156(3). 590–602. 130 indexed citations

14.

Becker, Kerstin, Claudia Vollbrecht, Jana Fassunke, et al.. (2013). Deep ion sequencing of amplicon adapter ligated libraries: a novel tool in molecular diagnostics of formalin fixed and paraffin embedded tissues. Journal of Clinical Pathology. 66(9). 803–806. 7 indexed citations

15.

Chatterjee, Sampurna, Lukas C. Heukamp, Jakob Schöttle, et al.. (2013). Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. Journal of Clinical Investigation. 123(4). 1732–1740. 164 indexed citations

16.

Rabenhorst, Anja, Max Schlaak, Lukas C. Heukamp, et al.. (2012). Mast cells play a protumorigenic role in primary cutaneous lymphoma. Blood. 120(10). 2042–2054. 105 indexed citations

17.

Heuckmann, Johannes M., Hyatt Balke‐Want, Florian Malchers, et al.. (2012). Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants. Clinical Cancer Research. 18(17). 4682–4690. 201 indexed citations

18.

Schulte, Johannes H., Lukas C. Heukamp, Theresa Thor, et al.. (2012). ALK(F1174L) is a driving oncogene of neuroblastoma in transgenic mice. Pediatric Blood & Cancer. 59(6). 989–989. 1 indexed citations

19.

Künkele, Annette, Katleen De Preter, Jo Vandesompele, et al.. (2011). Pharmacological activation of the p53 pathway by nutlin-3 inhibits medulloblastoma cell proliferation in vitro and in vivo. European Journal of Pediatrics. 170(2). 267–268. 1 indexed citations

20.

Hall, Thorbald van, Jeroen van Bergen, Peter A. van Veelen, et al.. (2000). Identification of a Novel Tumor-Specific CTL Epitope Presented by RMA, EL-4, and MBL-2 Lymphomas Reveals Their Common Origin. The Journal of Immunology. 165(2). 869–877. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact